Thomas E Prisinzano

List of Publications by Year
in descending order

155 papers	5,329 citations	61984 43 h-index	114465 63 g-index
166 all docs	166 docs citations	166 times ranked	4774 citing authors

#	Article	IF	Citations
1	Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development. Biochemical Pharmacology, 2022, 195, 114868.	4.4	2
2	Sex Differences in Kappa Opioid Receptor Agonist Mediated Attenuation of Chemotherapy-Induced Neuropathic Pain in Mice. Frontiers in Pharmacology, 2022, 13, 813562.	3.5	4
3	Rational inhibitor design for Pseudomonas aeruginosa salicylate adenylation enzyme PchD. Journal of Biological Inorganic Chemistry, 2022, 27, 541-551.	2.6	5
4	The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys. Pharmacology Biochemistry and Behavior, 2022, 217, 173394.	2.9	7
5	Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease. Clinical and Translational Immunology, 2021, 10, e1234.	3.8	16
6	Profile of a short-acting Îº-antagonist, LY2795050, on self-grooming behaviors, forced swim test and locomotor activity: sex comparison in mice. Journal of Psychopharmacology, 2021, 35, 579-590.	4.0	5
7	Reinforcing effects of synthetic cathinones in rhesus monkeys: Dose-response and behavioral economic analyses. Pharmacology Biochemistry and Behavior, 2021, 202, 173112.	2.9	13
8	Discriminative-Stimulus Effects of Synthetic Cathinones in Squirrel Monkeys. International Journal of Neuropsychopharmacology, 2021, 24, 656-665.	2.1	3
9	The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats. Psychopharmacology, 2021, 238, 3463-3476.	3.1	10
10	Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent. Journal of Biomedical Science, 2021, 28, 62.	7.0	8
11	Rapid-Onset Anti-Stress Effects of a Kappa-Opioid Receptor Antagonist, LY2795050, Against Immobility in an Open Space Swim Paradigm in Male and Female Mice. Frontiers in Pharmacology, 2021, 12, 775317.	3.5	1
12	The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 782190.	2.4	9
13	Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126788.	2.2	4
14	The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain. Scientific Reports, 2020, 10, 16392.	3.3	28
15	Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain. Frontiers in Neuroscience, 2020, 14, 765.	2.8	20
16	Strategies for DevelopingÎºOpioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 332-348.	2.5	37
17	Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Design, Synthesis, and Evaluation of Analogues with Improved Potency and G-protein Activation Bias at the Î¼-Opioid Receptor. ACS Chemical Neuroscience, 2020, 11, 1781-1790.	3.5	22
18	The Intriguing Effects of Substituents in the N-Phenethyl Moiety of Norhydromorphone: A Bifunctional Opioid from a Set of â€œTail Wags Dogâ€•Experiments. Molecules, 2020, 25, 2640.	3.8	10

#	Article	IF	Citations
19	G-Protein biased opioid agonists: 3-hydroxy-N-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9. RSC Medicinal Chemistry, 2020, 11, 896-904.	3.9	10
20	Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys. Psychopharmacology, 2020, 237, 1471-1480.	3.1	34
21	The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodoneâ€™s conditioned rewarding effects in male rats. Behavioural Pharmacology, 2020, 31, 792-797.	1.7	10
22	NeuroChat with Professor Thomas E. Prisinzaro. ACS Chemical Neuroscience, 2020, 11, 3993-3994.	3.5	0
23	Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an In Vitro High-Throughput Screening Assay. Journal of Virology, 2019, 93, .	3.4	12
24	Impact of Pharmacological Manipulation of the Î¹-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 1-8.	2.5	27
25	Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 487-499.	2.5	35
26	Stuffed Methyltransferase Catalyzes the Penultimate Step of Pyochelin Biosynthesis. Biochemistry, 2019, 58, 665-678.	2.5	10
27	Pharmacological Characterization of Kappa Opioid Receptor Agonists. FASEB Journal, 2019, 33, 663.14.	0.5	0
28	Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice. Neuroscience Letters, 2018, 673, 19-23.	2.1	12
29	Scalable Regioselective and Stereoselective Synthesis of Functionalized (E)-4-Iodobut-3-en-1-ols: Gram-Scale Total Synthesis of Fungal Decanolides and Derivatives. Journal of Organic Chemistry, 2018, 83, 980-992.	3.2	9
30	Novel psychotherapeutics â€“ a cautiously optimistic focus on Hallucinogens. Expert Review of Clinical Pharmacology, 2018, 11, 1-3.	3.1	26
31	Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents. Molecules, 2018, 23, 2602.	3.8	29
32	Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Drug and Alcohol Dependence, 2018, 192, 285-293.	3.2	6
33	Abuseâ€Related Discriminative Stimulus Effects of Synthetic Cathinones. FASEB Journal, 2018, 32, 822.1.	0.5	0
34	The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and Î²-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects. Psychopharmacology, 2017, 234, 2499-2514.	3.1	24
35	Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability. Journal of Medicinal Chemistry, 2017, 60, 3866-3878.	6.4	24
36	Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone. Brain Research, 2017, 1662, 75-86.	2.2	20

#	Article	IF	Citations
37	Synthesis and Opioid Activity of Tyr¹â€Ï[(Z)CF=CH]â€Gly² and Tyr¹â€Ï[(S)/(R)â€CF₃CHâ€NH]â€Gly² Leuâ€enkephalin Fluorinated Peptidomimetics. ChemMedChem, 2017, 12, 571-576.	3.2	26
38	Modular Approach to pseudo-Neoclerodanes as Designer Îº-Opioid Ligands. Organic Letters, 2017, 19, 5414-5417.	4.6	12
39	Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene. Journal of Natural Products, 2017, 80, 2094-2100.	3.0	18
40	The unique psychostimulant profile of (Â±)â€modafinil: investigation of behavioral and neurochemical effects in mice. European Journal of Neuroscience, 2017, 45, 167-174.	2.6	32
41	Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting Î¼ Opioid Analgesic with Reduced Abuse Liability. Journal of Medicinal Chemistry, 2016, 59, 11027-11038.	6.4	35
42	Predicted mode of Binding of Non-Nitrogenous Î¼-Opioid Receptor Ligands by Metadynamics. Biophysical Journal, 2016, 110, 90a.	0.5	2
43	Holo Structure and Steady State Kinetics of the Thiazolinyl Imine Reductases for Siderophore Biosynthesis. Biochemistry, 2016, 55, 5423-5433.	2.5	14
44	Behavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats. Neuropsychopharmacology, 2016, 41, 402-409.	5.4	56
45	Role of Ventral Subiculum in Context-Induced Relapse to Alcohol Seeking after Punishment-Imposed Abstinence. Journal of Neuroscience, 2016, 36, 3281-3294.	3.6	103
46	Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. Journal of Psychopharmacology, 2016, 30, 323-329.	4.0	12
47	N-Acetyl-S-(N,N-diethylcarbamoyl) cysteine in rat nucleus accumbens, medial prefrontal cortex, and in rat and human plasma after disulfiram administration. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 518-525.	2.8	3
48	Functional Selectivity of Kappa Opioid Receptor Agonists in Peripheral Sensory Neurons. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 174-182.	2.5	30
49	Potency enhancement of the Îº-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif. Bioorganic and Medicinal Chemistry, 2015, 23, 3948-3956.	3.0	7
50	Modafinil and its metabolites enhance the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Psychopharmacology, 2015, 232, 2463-2479.	3.1	15
51	Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPÎ³S binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting. Neuropharmacology, 2015, 99, 131-141.	4.1	24
52	Structureâ€“Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation While Preserving G Protein Over Î²Arrestin2 Signaling Bias. ACS Chemical Neuroscience, 2015, 6, 1411-1419.	3.5	48
53	Azaphilones Inhibit Tau Aggregation and Dissolve Tau Aggregates in Vitro. ACS Chemical Neuroscience, 2015, 6, 751-760.	3.5	42
54	Investigation of the role of Î²arrestin2 in kappa opioid receptor modulation in a mouse model of pruritus. Neuropharmacology, 2015, 99, 600-609.	4.1	38

#	Article	IF	Citations
55	The Importance of Molecular Design Principles in Delivering High Quality Pharmaceutical Candidates. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 177-191.	0.6	1
56	Salvinorin A Analogs and Other Kappa-Opioid Receptor Compounds as Treatments for Cocaine Abuse. Advances in Pharmacology, 2014, 69, 481-511.	2.0	47
57	Synthesis and Î¹-Opioid Receptor Activity of Furan-Substituted Salvinorin A Analogues. Journal of Medicinal Chemistry, 2014, 57, 10464-10475.	6.4	87
58	Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology, 2014, 231, 2751-2758.	3.1	44
59	Expanding the results of a high throughput screen against an isochorismate-pyruvate lyase to enzymes of a similar scaffold or mechanism. Bioorganic and Medicinal Chemistry, 2014, 22, 5961-5969.	3.0	8
60	Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology, 2014, 86, 228-240.	4.1	69
61	Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A. Journal of Natural Products, 2014, 77, 1817-1824.	3.0	9
62	Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology, 2013, 226, 381-392.	3.1	101
63	Cannabinoid agonists increase the interaction between Î²-Arrestin 2 and ERK1/2 and upregulate Î²-Arrestin 2 and 5-HT2A receptors. Pharmacological Research, 2013, 68, 46-58.	7.1	21
64	Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors. Journal of Biological Chemistry, 2013, 288, 36703-36716.	3.4	123
65	LC-MS/MS quantification of salvinorin A from biological fluids. Analytical Methods, 2013, 5, 7042.	2.7	5
66	Palladium-Catalyzed Transformations of Salvinorin A, a Neoclerodane Diterpene from Salvia divinorum. Organic Letters, 2013, 15, 5936-5939.	4.6	12
67	Combined effects of modafinil and d-amphetamine in male Sprague–Dawley rats trained to discriminate d-amphetamine. Pharmacology Biochemistry and Behavior, 2013, 110, 208-215.	2.9	8
68	Special Issue in Honor of Lester A. Mitscher. Journal of Natural Products, 2013, 76, 303-304.	3.0	0
69	Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening. Journal of Chemical Information and Modeling, 2013, 53, 521-526.	5.4	58
70	Neoclerodanes as Atypical Opioid Receptor Ligands. Journal of Medicinal Chemistry, 2013, 56, 3435-3443.	6.4	19
71	Design, Synthesis, and Biological Evaluation of Aminoalkylindole Derivatives as Cannabinoid Receptor Ligands with Potential for Treatment of Alcohol Abuse. Journal of Medicinal Chemistry, 2013, 56, 4537-4550.	6.4	39
72	The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats. European Journal of Pharmacology, 2013, 720, 69-76.	3.5	16

#	Article	IF	Citations
73	Modafinil alone and in combination with low dose amphetamine does not establish conditioned place preference in male sprague-dawley rats.. Experimental and Clinical Psychopharmacology, 2013, 21, 252-258.	1.8	15
74	Development of functionally selective agonists at the kappa opioid receptor (KOR). FASEB Journal, 2013, 27, lb551.	0.5	0
75	Development of biased agonists at the kappa opioid receptor.. FASEB Journal, 2013, 27, .	0.5	2
76	A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats. Behavioural Pharmacology, 2012, 23, 162-170.	1.7	20
77	Permeation and metabolism of cocaine in the nasal mucosa. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 255-262.	1.6	5
78	Behavioral Effects and Central Nervous System Levels of the Broadly Available Î¹-Agonist Hallucinogen Salvinorin A Are Affected by P-Glycoprotein Modulation In Vivo. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 802-808.	2.5	19
79	(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a Small Molecule Inhibitor Probe for the Study of Respiratory Syncytial Virus Infection. Journal of Medicinal Chemistry, 2012, 55, 8582-8587.	6.4	14
80	Reinstatement of methamphetamine seeking in male and female rats treated with modafinil and allopregnanolone. Drug and Alcohol Dependence, 2012, 120, 233-237.	3.2	50
81	Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence, 2012, 121, 181-188.	3.2	53
82	R-Modafinil (Armodafinil): A Unique Dopamine Uptake Inhibitor and Potential Medication for Psychostimulant Abuse. Biological Psychiatry, 2012, 72, 405-413.	1.3	121
83	Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. ACS Chemical Neuroscience, 2012, 3, 221-236.	3.5	42
84	Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochemical Pharmacology, 2012, 83, 952-961.	4.4	143
85	Semisynthetic neoclerodanes as kappa opioid receptor probes. Bioorganic and Medicinal Chemistry, 2012, 20, 3100-3110.	3.0	31
86	Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A. MedChemComm, 2011, 2, 1217.	3.4	36
87	Neuropharmacology of the Naturally Occurring Î¹-Opioid Hallucinogen Salvinorin A. Pharmacological Reviews, 2011, 63, 316-347.	16.0	106
88	Opioid Receptor Probes Derived from Cycloaddition of the Hallucinogen Natural Product Salvinorin A. Journal of Natural Products, 2011, 74, 718-726.	3.0	30
89	Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug and Alcohol Dependence, 2011, 115, 150-155.	3.2	120
90	SARs at the Monoamine Transporters for a Novel Series of Modafinil Analogues. ACS Medicinal Chemistry Letters, 2011, 2, 48-52.	2.8	60

#	Article	IF	Citations
91	Identification of unprecedented purine-containing compounds, the zingerines, from ginger rhizomes (Zingiber officinale Roscoe) using a phase-trafficking approach. Phytochemistry, 2011, 72, 935-941.	2.9	13
92	Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys.. Experimental and Clinical Psychopharmacology, 2010, 18, 395-408.	1.8	35
93	The discriminative effects of the Î°-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects. Psychopharmacology, 2010, 210, 253-262.	3.1	36
94	Kappa opioids and the modulation of pain. Psychopharmacology, 2010, 210, 109-119.	3.1	95
95	Identification of a novel â€œalmost neutralâ€•Î¼â€opioid receptor antagonist in CHO cells expressing the cloned human Î¼â€opioid receptor. Synapse, 2010, 64, 280-288.	1.2	24
96	Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors. Biochemical Journal, 2010, 431, 51-61.	3.7	41
97	Synthesis of Neoclerodane Diterpenes and Their Pharmacological Effects. Topics in Current Chemistry, 2010, 299, 141-185.	4.0	13
98	New therapeutic potential for psychoactive natural products. Natural Product Reports, 2010, 27, 23-31.	10.3	12
99	Uptake, Distribution and Diffusivity of Reactive Fluorophores in Cells: Implications toward Target Identification. Molecular Pharmaceutics, 2010, 7, 1301-1310.	4.6	49
100	Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 738-746.	2.5	169
101	Utilizing nature as a source of new probes for opioid pharmacology. Future Medicinal Chemistry, 2009, 1, 285-301.	2.3	3
102	Unconditioned Behavioral Effects of the Powerful Î°-Opioid Hallucinogen Salvinorin A in Nonhuman Primates: Fast Onset and Entry into Cerebrospinal Fluid. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 588-597.	2.5	52
103	Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacology Biochemistry and Behavior, 2009, 94, 244-249.	2.9	65
104	Synthetic studies on neoclerodane diterpenes from Salvia splendens: oxidative modifications of ring A. Tetrahedron, 2009, 65, 1708-1715.	1.9	9
105	Chemical methods for the synthesis and modification of neoclerodane diterpenes. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5490-5495.	2.2	19
106	Natural Products as Tools for Neuroscience: Discovery and Development of Novel Agents to Treat Drug Abuse. Journal of Natural Products, 2009, 72, 581-587.	3.0	52
107	Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 471-477.	4.3	50
108	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors. Organic and Biomolecular Chemistry, 2009, 7, 3748.	2.8	24

#	Article	IF	Citations
109	Mitochondrial Targeted Coenzyme Q, Superoxide, and Fuel Selectivity in Endothelial Cells. PLoS ONE, 2009, 4, e4250.	2.5	18
110	Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of opioid receptor affinity. Tetrahedron, 2008, 64, 10041-10048.	1.9	30
111	Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochemical Pharmacology, 2008, 75, 2-16.	4.4	77
112	Salvinorin A Analogs as Probes in Opioid Pharmacology. Chemical Reviews, 2008, 108, 1732-1743.	47.7	90
113	Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors. Brain Research Bulletin, 2008, 77, 49-54.	3.0	18
114	Gedunin, a Novel Hsp90 Inhibitor: Semisynthesis of Derivatives and Preliminary Structureâ^'Activity Relationships. Journal of Medicinal Chemistry, 2008, 51, 6495-6502.	6.4	146
115	Herkinorin Analogues with Differential Î²-Arrestin-2 Interactions. Journal of Medicinal Chemistry, 2008, 51, 2421-2431.	6.4	62
116	The Effects of Herkinorin, the First Î¼-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 154-160.	2.5	14
117	Effects of Salvinorin A, a Îº-Opioid Hallucinogen, on a Neuroendocrine Biomarker Assay in Nonhuman Primates with High Îº-Receptor Homology to Humans. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 300-306.	2.5	54
118	Salvinorin A: Allosteric Interactions at the Î¼-Opioid Receptor. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 801-810.	2.5	67
119	Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum:â€‰ Preparation and Opioid Receptor Activity of Salvinicin Analogues. Journal of Medicinal Chemistry, 2007, 50, 3596-3603.	6.4	46
120	Flavonoids as Opioid Receptor Ligands:â€‰ Identification and Preliminary Structureâ^'Activity Relationships. Journal of Natural Products, 2007, 70, 1278-1282.	3.0	66
121	DAT/SERT selectivity of flexible GBR 12909 analogs modeled using 3D-QSAR methods. Bioorganic and Medicinal Chemistry, 2007, 15, 1146-1159.	3.0	16
122	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Exploration of the 1-position. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6111-6115.	2.2	32
123	A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) Î¼-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse, 2007, 61, 166-175.	1.2	57
124	Mu opioid receptor activation without arrestinâ€interactions; a pharmacological approach.. FASEB Journal, 2007, 21, A426.	0.5	0
125	Design and Synthesis of Promiscuous High-Affinity Monoamine Transporter Ligands:Â Unraveling Transporter Selectivity. Journal of Medicinal Chemistry, 2006, 49, 1766-1772.	6.4	17
126	Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: I. Expression and Role of Cytochromes P450. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 488-496.	2.5	38

#	Article	IF	Citations
127	Synthetic Studies of Neoclerodane Diterpenes fromSalviadivinorum:Â Semisynthesis of Salvinicins A and B and Other Chemical Transformations of Salvinorin Aâ€. Journal of Natural Products, 2006, 69, 107-112.	3.0	52
128	Synthesis of Salvinorin A Analogues as Opioid Receptor Probes. Journal of Natural Products, 2006, 69, 914-918.	3.0	52
129	Role of dopamine transporter (DAT) in dopamine transport across the nasal mucosa. Life Sciences, 2006, 79, 1391-1398.	4.3	25
130	Structureâ€“activity relationships of substituted N-benzyl piperidines in the GBR series: Synthesis of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(2-trifluoromethylbenzyl)piperidine, an allosteric modulator of the serotonin transporter. Bioorganic and Medicinal Chemistry, 2006, 14, 3967-3973.	3.0	14
131	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Selective modification of the furan ring. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3170-3174.	2.2	47
132	Reactive Oxygen and Targeted Antioxidant Administration in Endothelial Cell Mitochondria. Journal of Biological Chemistry, 2006, 281, 39766-39775.	3.4	106
133	Determination of Salvinorin A in body fluids by high performance liquid chromatographyâ€“atmospheric pressure chemical ionization. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 818, 221-225.	2.3	58
134	Enantioselective synthesis of (2R,3R)- and (2S,3S)-2-[(3-chlorophenyl)-(2-methoxyphenoxy)methyl]morpholine. Tetrahedron: Asymmetry, 2005, 16, 2249-2256.	1.8	13
135	Salvinicins A and B, New Neoclerodane Diterpenes fromSalviadivinorum. Organic Letters, 2005, 7, 3017-3020.	4.6	57
136	Pharmacokinetics of the plant-derived Î¹-opioid hallucinogen salvinorin A in nonhuman primates. Synapse, 2005, 58, 208-210.	1.2	74
137	Neoclerodane Diterpenes as a Novel Scaffold for Î¼ Opioid Receptor Ligandsâ€. Journal of Medicinal Chemistry, 2005, 48, 4765-4771.	6.4	139
138	Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sciences, 2005, 78, 527-531.	4.3	99
139	A concise method for the preparation of deuterium-labeled cortisone: Synthesis of [6,7-H]cortisone. Steroids, 2005, 70, 763-769.	1.8	4
140	κ Opioids as potential treatments for stimulant dependence. AAPS Journal, 2005, 7, E592-E599.	4.4	62
141	Development of Neurochemical Normalization (“Agonist Substitution”) Therapeutics for Stimulant Abuse: Focus on the Dopamine Uptake Inhibitor, GBR12909. Current Medicinal Chemistry - Central Nervous System Agents, 2004, 4, 47-59.	0.5	12
142	Synthesis and determination of the absolute configuration of the enantiomers of modafinil. Tetrahedron: Asymmetry, 2004, 15, 1053-1058.	1.8	55
143	Synthesis and determination of the absolute stereochemistry of the enantiomers of adrafinil and modafinil. Tetrahedron: Asymmetry, 2004, 15, 3811-3815.	1.8	30
144	2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4697-4699.	2.2	5

#	Article	IF	Citations
145	A facile method for the preparation of deuterium labeled salvinorin A: synthesis of [2,2,2-2H3]-salvinorin A. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5099-5102.	2.2	62
146	Synthesis and Dopamine Transporter Affinity of Chiral 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as Potential Cocaine Abuse Therapeutic Agents.. ChemInform, 2003, 34, no.	0.0	0
147	A concise synthesis of (S)-(+)-1-(4-{2-[bis-(4-fluorophenyl)methoxy]-ethyl}piperazin-1-yl)-2-phenylpropan-2-ol dimaleate. Tetrahedron: Asymmetry, 2003, 14, 3285-3289.	1.8	8
148	Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 553-556.	2.2	17
149	High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse, 2003, 50, 233-239.	1.2	56
150	Further exploration of 1-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}piperazine (GBR 12909): role of N-aromatic, N-heteroaromatic, and 3-oxygenated N-phenylpropyl substituents on affinity for the dopamine and serotonin transporter. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1385-1389.	2.2	11
151	Structureâ^'Activity Relationship Studies of Highly Selective Inhibitors of the Dopamine Transporter:â€‰ N-Benzylpiperidine Analogues of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine. Journal of Medicinal Chemistry, 2003, 46, 1465-1469.	6.4	17
152	Piperidine Analogues of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 4371-4374.	6.4	17
153	Synthesis and biological activity of 8Î²-substituted hydrocodone indole and hydromorphone indole derivatives. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 165-168.	2.2	28
154	Imidazoline-modified benzylimidazolines as h5-HT1D/1B serotonergic ligands. Bioorganic and Medicinal Chemistry, 2001, 9, 613-619.	3.0	26
155	Benzylimidazolines as h5-HT1B/1D Serotonin Receptor Ligands: A Structureâ^'Affinity Investigation. Journal of Medicinal Chemistry, 1998, 41, 2243-2251.	6.4	17